Zynerba Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Armando Anido

Algemeen directeur

US$1.9m

Totale compensatie

Percentage CEO-salaris	33.6%
Dienstverband CEO	9yrs
Eigendom CEO	1.9%
Management gemiddelde ambtstermijn	6.8yrs
Gemiddelde ambtstermijn bestuur	8.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Armando Anido's beloning veranderd ten opzichte van Zynerba Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$633k	-US$35m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$38m
Dec 31 2021	US$2m	US$603k	-US$37m
Sep 30 2021	n/a	n/a	-US$38m
Jun 30 2021	n/a	n/a	-US$37m
Mar 31 2021	n/a	n/a	-US$47m
Dec 31 2020	US$1m	US$585k	-US$51m
Sep 30 2020	n/a	n/a	-US$52m
Jun 30 2020	n/a	n/a	-US$45m
Mar 31 2020	n/a	n/a	-US$36m
Dec 31 2019	US$1m	US$568k	-US$33m
Sep 30 2019	n/a	n/a	-US$30m
Jun 30 2019	n/a	n/a	-US$36m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	US$2m	US$568k	-US$40m
Sep 30 2018	n/a	n/a	-US$40m
Jun 30 2018	n/a	n/a	-US$41m
Mar 31 2018	n/a	n/a	-US$37m
Dec 31 2017	US$2m	US$552k	-US$32m
Sep 30 2017	n/a	n/a	-US$31m
Jun 30 2017	n/a	n/a	-US$28m
Mar 31 2017	n/a	n/a	-US$26m
Dec 31 2016	US$901k	US$536k	-US$23m

Compensatie versus markt: De totale vergoeding ($USD 1.88M ) Armando } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.57K ).

Compensatie versus inkomsten: De vergoeding van Armando is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Armando Anido (65 yo)

9yrs

Tenure

US$1,881,402

Compensatie

Mr. Armando Anido, MBA, has been the Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, Inc. since October 2014. Mr. Anido has been an Independent Director of SCYNEXIS, Inc. since January 21,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Terri Sebree	President	9yrs	US$1.38m	1.18% $ 775.1k
James Fickenscher	CFO & VP of Corporate Development (Leave of Absence)	7.1yrs	US$1.26m	0.75% $ 491.5k
Kenneth Jones	VP, Corporate Controller & Interim CFO	6.6yrs	geen gegevens	0.17% $ 111.2k
Albert Parker	Chief Legal Officer & Corporate Secretary	1.7yrs	geen gegevens	0.45% $ 295.1k
Joseph Apostolico	Vice President of Human Resources	5.6yrs	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0M40 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Armando Anido	Chairman & CEO	9yrs	US$1.88m	1.94% $ 1.3m
Kenneth Moch	Independent Director	8.2yrs	US$107.50k	0.15% $ 98.5k
Daniel Kisner	Independent Director	8.2yrs	US$105.00k	0.15% $ 98.5k
Warren Cooper	Lead Independent Director	8.2yrs	US$135.00k	0.15% $ 98.5k
John Butler	Independent Director	5.5yrs	US$102.50k	0.16% $ 105.0k
William Federici	Independent Director	8.2yrs	US$110.00k	0.15% $ 98.5k
Steven Siegel	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Randi Hagerman	Member of Scientific Advisory Board	8yrs	geen gegevens	geen gegevens
Elizabeth Berry-Kravis	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Nicole Tartaglia	Member of Scientific Advisory Board	7yrs	geen gegevens	geen gegevens
Pamela Stephenson	Independent Director	4.7yrs	US$100.00k	0.15% $ 98.5k
Craig Erikson	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

8.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0M40 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.2 jaar).

Zynerba Pharmaceuticals Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Zynerba Pharmaceuticals, Inc. acquired Epygenix Therapeutics, Inc for $680 million.

Zynerba Pharmaceuticals Files Form 15

Zynerba Pharmaceuticals, Inc.(NasdaqGM:ZYNE) dropped from NASDAQ Composite Index

Harmony Biosciences Holdings, Inc. (NasdaqGM:HRMY) completed the acquisition of Zynerba Pharmaceuticals, Inc. (NasdaqCM:ZYNE).

Zynerba Pharmaceuticals, Inc.(NasdaqCM:ZYNE) dropped from S&P TMI Index

New minor risk - Profitability

Zynerba Pharmaceuticals Provides Nasdaq Compliance Update

New major risk - Financial position

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2023

Forecast to breakeven in 2025

Zynerba Pharmaceuticals Gets an Additional 180 Calendar Day Period, or Until October 30, 2023 to Regain Compliance with the Bid Price Rule

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals Announces Update on Reconnect, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the Annual Meeting of the American College of Neuropsychopharmacology

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel(TM) in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Receives a Deficiency Letter from Nasdaq

Zynerba Pharmaceuticals, Inc. Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 Inspire Trial in 22Q11.2 Deletion Syndrome At the National Organization for Rare Disorders (Nord) Rare Diseases and Orphan Products Breakthrough Summit

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals, Inc. Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome At the International Society for Autism Research Annual Meeting

Insufficient new directors

Zynerba Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Insufficient new directors

Insufficient new directors

Zynerba Pharmaceuticals, Inc. Announces European Commission Grants Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Trial of Zygel in 22Q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. Announces Executive Changes

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Publication of Results of Phase 2 BELIEVE Open-Label Study of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies (DEE) in JAMA Network Open

Pomerantz LLP and The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement Against Zynerba Pharmaceuticals, Inc

Forecast to breakeven in 2025

Zynerba Pharmaceuticals, Inc. Receives Guidance from the U.S. Food and Drug Administration on Confirmatory Phase 3 Trial of Zygel in Patients with Fragile X Syndrome

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd